Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...

TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...

PALO ALTO, CA, UNITED STATES, August 13, 2025 / EINPresswire.com / -- Baylink Biosciences, a biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today ...

Antibody-Drug Conjugates (ADCs) are a fast-growing modality in both cancerous and non-cancerous indications. To date 15 ADCs have been approved by the regulatory agencies as therapies for various ...

DUBLIN--(BUSINESS WIRE)--The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key ...

Presentations to highlight preclinical data supporting the clear differentiation of Adcentrx's clinical-stage ADRX-0405 STEAP1 ADC and preclinical ADRX-0134 NaPi2b ADC Adcentrx to present new ...

MUNICH--(BUSINESS WIRE)--Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of the first patient in the 5-STAR 1-01 Phase I/IIa ...